Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution

Blood

Volumn 91, Issue 6, 1998, Pages 2197-2207

  Warren, Edus H ^a   Greenberg, Philip D ^b   Riddell, Stanley R ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA B ANTIGEN; HLA B27 ANTIGEN; HLA C ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ADOPTIVE TRANSFER; ALLELE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

EID: 0032521476     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.6.2197.2197_2197_2207     Document Type: Article

References (52)

1. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Fluornoy N, Storb R, Thomas ED: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664, 1985
2. Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AW, Gordon-Smith EC, Catovsky D, Galton DAG, Goldman JM: Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant 1:53, 1986
3. Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J, Terasaki P, Billing R, Feig S: Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 105:20, 1986
4. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, Leblond V, Michallet M, Dreyfus F, Ifrah N, Bordigoni A: Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2:175, 1987
5. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988
6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
7. Ringden O, Remberger M, Aschan J, Lungman P, Lonnqvist B, Markling L: Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplantation 58:887, 1994
8. Goulmy E: Human minor histocompatibility antigens. Curr Opin Immunol 8:75, 1996
9. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990
10. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation [letter]. Blood 79:1379, 1992
11. Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL: Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 10:301, 1992
12. Bar BM, Schattenberg A, Mensink EJ, Geurts Van Kessel A, Smetsers TF, Knops GH, Linders EH, De Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11:513, 1993
13. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993
14. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 12:125, 1993
15. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, Heinze B, Hubner G, Heimpel H, Arnold R: Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 56:1114, 1993
16. Szer J, Grigg AP, Phillips GL, Sheridan WP: Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 11:109, 1993
17. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
18. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377, 1994
19. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995
20. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Vanrhee F, Mittermueller J, Dewitte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995
21. Giralt S, Hester J, Huh Y, Hirschginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Vanbesien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337, 1995
22. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [see comments]. J Clin Oncol 15:433, 1997
23. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238, 1992
24. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against CMV in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995
25. Marijt WA, Veenhof WF, Brand A, Goulmy E, Fibbe WE, Willemze R, van Rood JJ, Falkenburg JH: Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells. J Exp Med 173:101, 1991
26. van Lochem EG, Bakker A, Hoefsmit EC, de Gast GC, Goulmy E: Analysis of dendritic-cell-induced primary T-cell responses between HLA genotypically identical individuals. Hum Immunol 44:181, 1995
27. Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ: A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 302:159, 1983
28. de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E: Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 149:1788, 1992
29. van Els CA, D'Amaro J, Pool J, Blokland E, Bakker A, van Elsen PJ, van Rood JJ, Goulmy E: Immunogenetics of human minor histocompatibility antigens: Their polymorphism and immunodominance. Immunogenetics 35:161, 1992
30. Dolstra H, Fredrix H, Preijers F, Goulmy E, Figdor CG, de Witte TM, van de Wiel-van Kemenade E: Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 158:560, 1997
31. 30a. van der Harst D, Goulmy E, Falkenburg JH, Kooij-Winkelaar YM, van Luxemburg-Heijs SA, Goselink HM, Brand A: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83:1060, 1994
32. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T: Alleles and haplotype frequencies for HLA and complement loci in various ethnic groups, in Tsuji K, Aizawa M, Sasasuki T (eds): HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference, vol 1. Oxford, UK, Oxford Science, 1992, p 1065
33. Rickinson AB, Rowe M, Hart IJ, Yao QY, Henderson LE, Rabin H, Epstein MA: T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: Studies with cyclosporin A. Cell Immunol 87:646, 1984
34. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD: Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795, 1991
35. Gubarev MI, Jenkin JC, Leppert MF, Buchanan GS, Otterud BE, Guilbert DA, Beatty PG: Localization to chromosome 22 of a gene encoding a human minor histocompatibility antigen. J Immunol 157: 5448, 1996
36. Marijt WA, Kernan NA, Diaz-Barrientos T, Veenhof WF, O'Reilly RJ, Willemze R, Falkenburg JH: Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplant 16:125, 1995
37. Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik AI, Hendrickson RC, Bishop CE, Hunt DF, Goulmy E, Engelhard VH: Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein. Science 269:1588, 1995
38. Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, Drijfhout JW, Shabanowitz J, Pierce R, Agulnik AI, Bishop CE, Hunt DF, Goulmy E, Engelhard VH: The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6:273, 1997
39. van Els CA, Bakker A, Zwinderman AH, Zwaan FE, van Rood JJ, Goulmy E: Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation 50:62, 1990
40. de Bueger M, Bakker A, Bontkes H, van Rood JJ, Goulmy E: High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: Absence of correlation with GVHD. Bone Marrow Transplant 11:363, 1993
41. Niederwieser D, Grassegger A, Aubock J, Herold M, Nachbaur D, Rosenmayr A, Gachter A, Nussbaumer W, Gaggl S, Ritter M, Huber C: Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 81:2200, 1993
42. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg F, Vossen J, Gratwohl A, Vogelsang G, van Houwelingen H, van Rood J: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334:281, 1996
43. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268:1476, 1995
44. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489, 1993
45. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35, 1994
46. Van den Eynde B, Peeters O, Debacker O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689, 1995
47. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P: BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167, 1995
48. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645, 1994
49. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730, 1997
50. Lupton SD, Brunton LL, Kalberg VA, Overell RW: Dominant positive and negative selection using a hygromycin phosphotransferasethymidine kinase fusion gene. Mol Cell Biol 11:3374, 1991
51. Riddell SR, Greenberg PD, Overell RW, Loughran TP, Gilbert MJ, Lupton SD, Agosti J, Scheeler S, Coombs RW, Corey L: Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther 3:319, 1992
52. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. Science 276:1719, 1997